
Xcelience, LLC
Advertisement
Articles by Xcelience, LLC


Sponsored Content
When the clinical protocol dictates and/or helps with patient compliance, it can be necessary for investigational drug products to be packaged in blinded blister cards (wallets) that contain two, or more, different strength products. The presence of different products (placebo and/or active strengths) inside a packaging suite clearly raises the potential for error. So to combat this, a whole series of physical segregation and process controls are put in place to act as safeguards against product mix-ups.
Advertisement
Latest Updated Articles
Considerations in the Development of Controlled Release FormulationsSeptember 1st 2015
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What Does TAUKLARIFY's Approval Mean for Alzheimer's Drug Developers?
2
Europe Tried to Ban Generative AI From Critical GMP. The Ban May Not Survive. It Does Not Matter.
3
Pharma's AI ROI Problem Isn't a Tech Problem but a Qualification Problem
4
Q&A: Why Is Halo Pharma Expanding Into Sterile Injectables Now?
5